Fluoroazomycin arabinoside F-18

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Fluoroazomycin arabinoside F-18
Accession Number
DB15134
Description

Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).

Type
Small Molecule
Groups
Investigational
Purchasing individual compounds or compound libraries for your research?
Learn More
Structure
Thumb
Weight
Average: 246.185
Monoisotopic: 246.062983101
Chemical Formula
C8H10FN3O5
Synonyms
  • 18F-FAZA

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
UG7I3Y42PV
CAS number
864084-85-5
InChI Key
LPZSRGRDVVGMMX-FJBGPTLJSA-N
InChI
InChI=1S/C8H10FN3O5/c9-3-4-5(13)6(14)7(17-4)11-2-1-10-8(11)12(15)16/h1-2,4-7,13-14H,3H2/t4-,5-,6+,7+/m1/s1/i9-1
IUPAC Name
(2S,3S,4S,5S)-2-[(¹⁸F)fluoromethyl]-5-(2-nitro-1H-imidazol-1-yl)oxolane-3,4-diol
SMILES

References

General References
Not Available
ChemSpider
2104828

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2TerminatedDiagnosticNeoplasms, Breast1
1Enrolling by InvitationDiagnosticNon-Rhabdo. Soft Tissue Sarcoma / Rhabdomyosarcomas1
1, 2TerminatedDiagnosticNeuroendocrine Tumours / Renal Cell Adenocarcinoma1
Not AvailableNot Yet RecruitingDiagnosticLocally Advanced Pancreatic Adenocarcinoma / Pancreatic Adenocarcinoma Non-resectable / Unresectable Pancreatic Cancer1
Not AvailableRecruitingDiagnosticSarcomas1
Not AvailableWithdrawnDiagnosticAdenocarcinoma of the Pancreas / Advanced Disease / Metastatic Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility13.0 mg/mLALOGPS
logP-0.45ALOGPS
logP-0.19ChemAxon
logS-1.3ALOGPS
pKa (Strongest Acidic)12.45ChemAxon
pKa (Strongest Basic)-0.016ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area110.65 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity49.71 m3·mol-1ChemAxon
Polarizability20.67 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created on May 20, 2019 08:52 / Updated on June 12, 2020 10:53

Logo pink
Are you using machine learning
in your drug discovery pipeline?
Learn more about integrating our machine-readable data into your algorithms, saving you time and money.